G Protein Coupled Receptors as Drug Targets: The Role of β-Arrestins

Author(s): Jasmin R. Dromey, Kevin D.G. Pfleger

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 8 , Issue 1 , 2008

Become EABM
Become Reviewer
Call for Editor


G protein coupled receptors (GPCRs) are extremely important drug targets and the β-arrestin intracellular scaffolding and adaptor proteins regulate major aspects of their pharmacology. β-arrestin binding to activated, GPCR kinase (GRK)-phosphorylated receptors has the capacity to terminate G protein coupling, internalize the receptors into clathrincoated vesicles and establish a secondary signaling complex independent of G protein signaling. These events appear to be differentially regulated by GRK phosphorylation, ubiquitination and potentially β-arrestin oligomerization, which are likely to be highly receptor and cell-type dependent. The role of β-arrestins in switching from G-protein dependent to independent signaling places them in a pivotal position to dictate the downstream effects of ligand binding. Consequently, we must appreciate the functioning of these molecules as we strive to discover and optimize new GPCR drug therapies for endocrine, metabolic and immune disorders.

Keywords: G protein coupled receptor, GPCR, β-arrestin, endocytosis, internalisation

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [51 - 61]
Pages: 11
DOI: 10.2174/187153008783928352

Article Metrics

PDF: 44